Skip Nav Destination
Issues
1 February 2018
-
Cover Image
Cover Image
ABOUT THE COVER
By combined utilization of the CRISPR/Cas9 system and the high-resolution melting analysis, a screening strategy for non-homologous end joining (NHEJ) inhibitors has been established. One of the hits from a drug library containing 1540 compounds is ouabain, a cardiotonic and antipsychotic agent that has the capacity to restrain NHEJ activity. The frontpage shows the neutral comet assay of HeLa cells treated with X-ray in the presence of ouabain. For more details, see the article by Du and colleagues on page 419. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
MCT Focus: Developmental Therapeutics in Radiation Oncology
Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner
Kamalakannan Palanichamy; Disha Patel; John R. Jacob; Kevin T. Litzenberg; Nicolaus Gordon; Kirstin Acus; Shin-ei Noda; Arnab Chakravarti
Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma
Ravi S. Narayan; Ana Gasol; Paul L.G. Slangen; Fleur M.G. Cornelissen; Tonny Lagerweij; Hou Y.Y.E. Veldman; Rogier Dik; Jaap van den Berg; Ben J. Slotman; Tom Würdinger; Daphne A. Haas-Kogan; Lukas J.A. Stalpers; Brigitta G. Baumert; Bart A. Westerman; Jan Theys; Peter Sminia
Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
Iris Eke; Adeola Y. Makinde; Molykutty J. Aryankalayil; Veit Sandfort; Sanjeewani T. Palayoor; Barbara H. Rath; Lance Liotta; Mariaelena Pierobon; Emanuel F. Petricoin; Matthew F. Brown; Jayne M. Stommel; Mansoor M. Ahmed; C. Norman Coleman
Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Blaz Groselj; Jia-Ling Ruan; Helen Scott; Jessica Gorrill; Judith Nicholson; Jacqueline Kelly; Selvakumar Anbalagan; James Thompson; Michael R.L. Stratford; Sarah J. Jevons; Ester M. Hammond; Cheryl L. Scudamore; Martin Kerr; Anne E. Kiltie
A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist
Akinori Morita; Ippei Takahashi; Megumi Sasatani; Shin Aoki; Bing Wang; Shinya Ariyasu; Kaoru Tanaka; Tetsuji Yamaguchi; Akiko Sawa; Yurie Nishi; Tatsuro Teraoka; Shohei Ujita; Yosuke Kawate; Chihiro Yanagawa; Keiji Tanimoto; Atsushi Enomoto; Mitsuru Nenoi; Kenji Kamiya; Yasushi Nagata; Yoshio Hosoi; Toshiya Inaba
Small Molecule Therapeutics
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
Yan Huang; Wei Hu; Jie Huang; Fangrong Shen; Yunjie Sun; Cristina Ivan; Sunila Pradeep; Robert Dood; Monika Haemmerle; Dahai Jiang; Lingegowda S. Mangala; Kyunghee Noh; Jean M. Hansen; Heather J. Dalton; Rebecca A. Previs; Archana S. Nagaraja; Michael McGuire; Nicholas B. Jennings; Russell Broaddus; Robert L. Coleman; Anil K. Sood
COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Fuli Wang; Hongyong Zhang; Ai-Hong Ma; Weimin Yu; Maike Zimmermann; Jun Yang; Sung Hee Hwang; Daniel Zhu; Tzu-yin Lin; Michael Malfatti; Kenneth W. Turteltaub; Paul T. Henderson; Susan Airhart; Bruce D. Hammock; Jianlin Yuan; Ralph W. de Vere White; Chong-Xian Pan
Cancer Biology and Translational Studies
Large Molecule Therapeutics
Author Choice
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Fu Li; May Kung Sutherland; Changpu Yu; Roland B. Walter; Lori Westendorf; John Valliere-Douglass; Lucy Pan; Ashley Cronkite; Django Sussman; Kerry Klussman; Michelle Ulrich; Martha E. Anderson; Ivan J. Stone; Weiping Zeng; Mechthild Jonas; Timothy S. Lewis; Maitrayee Goswami; Sa A. Wang; Peter D. Senter; Che-Leung Law; Eric J. Feldman; Dennis R. Benjamin
An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Rhonda C. Kines; Isabella Varsavsky; Sanghamitra Choudhary; Debaditya Bhattacharya; Sean Spring; Roger McLaughlin; Shin J. Kang; Hans E. Grossniklaus; Demetrios Vavvas; Stephen Monks; John R. MacDougall; Elisabet de los Pinos; John T. Schiller
Models and Technologies
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.